Debra Miller, founder of CureDuchenne, discusses research activity in Duchenne muscular dystrophy (DMD) and the role of the advocate in this rare disease.

Debra founded CureDuchenne in 2003 with her husband after their only son was diagnosed with Duchenne. The funds CureDuchenne raise support research programs aimed at treating and curing the disease.

CureDuchenne has leveraged more than $1.3 billion in follow-on investment from venture capital, biotech, and pharmaceutical companies to fund Duchenne research. To date, 10 CureDuchenne research projects have advanced into human clinical trials, including one that resulted in the first FDA approved drug for Duchenne.